A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States

Expanding serotype coverage of pneumococcal conjugate vaccines (PCVs) to target prevailing disease-causing serotypes could further reduce disease burden. To address this need, 2 different PCVs have been investigated: a 20-valent PCV (PCV20; includes the 13 serotypes in the 13-valent PCV [PCV13] plus...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	David Fitz-Patrick, Mariano Young Jr, Daniel A. Scott, Ingrid L. Scully, Gary Baugher, Yahong Peng, Kathrin U. Jansen, William Gruber, Wendy Watson
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Taylor & Francis Group 2021-07-01
Schriftenreihe:	Human Vaccines & Immunotherapeutics
Schlagworte:	streptococcus pneumoniae clinical trial pneumococcal conjugate vaccine immunogenicity safety pcv20 cpcv7
Online-Zugang:	http://dx.doi.org/10.1080/21645515.2020.1863177
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!